Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06618014 | Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)(NeoTOP) | active not recruiting | Phase 2 | 51 | Sun Yat-sen UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07394387 | Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer. | recruiting | Phase 2 | 58 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 |
| May 15, 2026 |
| clinicaltrials |
| NCT07053085 | A Study of Surgery and Radiotherapy in People With Breast Cancer | recruiting | Phase 2 | 178 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07283692 | Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) | recruiting | Phase 2 | 46 | RenJi HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03941730 | Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer | active not recruiting | Phase 2 | 8 | Mayo ClinicOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07581795 | Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer(SPECTACLE) | not yet recruiting | Phase 2 | 140 | Fudan UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05319873 | Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05498896 | Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC(BARBICAN) | active not recruiting | Phase 2 | 146 | Queen Mary University of LondonOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04771871 | MicroRNA Profiles in Triple Negative Breast Cancer(TARMAC) | recruiting | Phase 2 | 42 | University College Hospital, IbadanOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT01042379 | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer(I-SPY) | recruiting | Phase 2 | 5,000 | QuantumLeap Healthcare CollaborativeOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04647916 | Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases | active not recruiting | Phase 2 | 44 | SWOG Cancer Research NetworkNETWORK | 1 | May 6, 2026 | clinicaltrials |
| NCT06845319 | NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients(NeoCARD) | recruiting | Phase 2 | 43 | Medical University of South CarolinaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04305834 | Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. | recruiting | Phase 2 | 43 | City of Hope Medical CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04434040 | Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | recruiting | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT01245712 | Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer | active not recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04468061 | Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | recruiting | Phase 2 | 110 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06172127 | PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer(DEMETHER) | active not recruiting | Phase 2 | 165 | MedSIROTHER | 5 | Apr 29, 2026 | clinicaltrials |
| NCT05645380 | Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC(NeoTRACT) | active not recruiting | Phase 2 | 139 | University of Kansas Medical CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07276880 | Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer(P-RAD(+)TN-DCT) | recruiting | Phase 2 | 32 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT02734290 | Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 29 | Providence Health & ServicesOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06434064 | Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer | recruiting | Phase 2 | 30 | Roswell Park Cancer InstituteOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07443943 | A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial(AIMSS-RPS) | recruiting | Phase 2 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03756298 | Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | active not recruiting | Phase 2 | 284 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07069595 | PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease(PREDICT-RD) | recruiting | Phase 2 | 78 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06134375 | A Study of Tetrathiomolybdate (TM) Plus Capecitabine | recruiting | Phase 1 / Phase 2 | 204 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer(InCITe) | active not recruiting | Phase 2 | 145 | Laura Huppert, MD, BAOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06042569 | Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial | recruiting | Phase 2 | 174 | City of Hope Medical CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06492759 | High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer | recruiting | Phase 2 | 29 | Emory UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05749588 | FUSCC Refractory TNBC Platform Study (FUTURE2.0) | recruiting | Phase 2 | 120 | Fudan UniversityOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT02876107 | Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | active not recruiting | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07045311 | JS207 Combination Therapy in Triple-negative Breast Cancer | recruiting | Phase 2 | 80 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02802423 | Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. | not yet recruiting | Phase 1 / Phase 2 | 44 | BioLite, Inc.INDUSTRY | 0 | Apr 13, 2026 | clinicaltrials |
| NCT03650894 | Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients | active not recruiting | Phase 2 | 30 | Providence Health & ServicesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07112053 | A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer | recruiting | Phase 2 | 40 | University of WashingtonOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07510802 | Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07509515 | QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC. | not yet recruiting | Phase 2 | 60 | Fudan UniversityOTHER | 0 | Apr 3, 2026 | clinicaltrials |
| NCT04569747 | A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer(ADEPT) | active not recruiting | Phase 2 | 393 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06365788 | Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer(ABBICAR) | recruiting | Phase 2 | 53 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06768931 | Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer | recruiting | Phase 2 | 192 | Sun Yat-sen UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06450873 | Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery | recruiting | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT01525966 | Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer | active not recruiting | Phase 2 | 67 | City of Hope Medical CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07499999 | Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer(BabyTEARS) | not yet recruiting | Phase 2 | 140 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07486089 | Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)(DUAL-NK-BC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06650748 | Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer(NeoMARS) | enrolling by invitation | Phase 2 | 100 | Peking UniversityOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05227664 | A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer | active not recruiting | Phase 2 | 120 | AkesoINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07457359 | Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer(NEOTRIO-2) | recruiting | Phase 2 | 18 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07458204 | Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer(EPPIL) | not yet recruiting | Phase 2 | 760 | Institut Jean-GodinotOTHER | 1 | Mar 9, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 15, 2026source: clinicaltrials